X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Amgen and EVOQ Therapeutics are collaborating on preclinical development of novel drugs using EVOQ's NanoDisc platform. Amgen is responsible for clinical development and commercialization of the resulting products.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 18, 2023
Details:
Under the agreement, Gilead has the option to exclusively license rights to EVOQ’s NanoDisc technology to pursue product candidates for RA and lupus indications and will be responsible for clinical development and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $658.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2023
Details:
Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
